Xinglong Jiang, Ph.D.

Senior Vice President Preclinical Development

Dr. Jiang leads Structure’s DMPK, CMC, and toxicology activities. He has more than 26 years of experience leading teams in developing safe and robust manufacturing processes for drug substances and drug products in cGMP environments. Prior to Structure, Dr. Jiang held positions of increasing responsibility at companies including Roche, Novartis, AstraZeneca, and Janssen. He has experience in the preclinical, clinical, and commercial stages of drug development, including contributions to two marketed drugs, Xenical® and Xeloda®. Dr. Jiang has published more than 35 patents and peer-reviewed scientific papers. Dr. Jiang earned his Ph.D. in organic chemistry from the University of Connecticut and his M.S. and B.S. from Beijing Normal University.